Minimal pain
Reduced postoperative discomfort compared with open procedures.
Back to ServicesServices · Minimally Invasive Surgeries
Minimally invasive surgeries for orthopaedic oncology
Image-guided procedures performed through sub-10 mm incisions to diagnose and treat musculoskeletal tumours — with millimetre precision, day-care recovery and outcomes that rival open surgery.
93–98%
Diagnostic accuracy
84–100%
Therapeutic success
<10 mm
Typical incision
Why MIS
The hallmarks of minimally invasive surgery
Less trauma, more precision — without compromising oncological control.
Small incisions
Often less than 10 mm with excellent cosmetic outcomes.
Early recovery
Day-care procedures with rapid return to activities.
High precision
CT, MRI, ultrasound and fluoroscopy guide millimetre-accurate targeting.
Reproducible protocols
Standardised workflows that deliver consistent outcomes.
Cost-effective
Lower overall healthcare costs through reduced hospitalisation.
The core procedures
Image-guided techniques we offer
Each technique is matched to the lesion type, location and the patient's goals — diagnosis, cure, palliation or stabilisation.
Diagnosis
Core needle biopsy
Image-guided tissue sampling using 14–18 gauge needles under CT, ultrasound or MRI guidance.
- Diagnostic accuracy: 93.4–97.9% for musculoskeletal tumours
- Yield rate: 96% even in complex cases
- Safety profile: No tract recurrence reported in recent studies
Cystic lesions
Percutaneous sclerotherapy
Day-care injection of 3% polidocanol (max 4 mL/session) after image-guided aspiration and curettage of septations.
- Aneurysmal bone cysts: 84–100% healing with 2–4 injections
- Simple / unicameral cysts: 85–95% cavity obliteration
- Recurrent ABCs: 92% healing after failed surgery
Thermal ablation
Percutaneous radiofrequency ablation (RFA)
Bipolar navigational electrodes deliver focal heat through a single entry point — no grounding pad required.
- Osteoid osteoma: 94–100% success
- Recurrence: Only 1.6–5.7% need repeat treatment
- Safety: Real-time temperature monitoring, low skin burn risk
Cold ablation
Percutaneous cryoablation
Ice balls at −40°C to −160°C cause cellular dehydration, protein denaturation and vascular thrombosis.
- Bone metastases: 97.7% technical success, 4.5-point VAS pain drop
- Desmoid fibromatosis: 85.8% non-progressive disease
- Pain relief: From week 1, sustained through 24 weeks
Stabilisation
Percutaneous cementoplasty
PMMA injection restores skeletal strength and prevents pathological fracture, often combined with thermal ablation.
- Pain relief: VAS 6.1 → 2.1 at 1 month for metastases
- Stabilisation: Immediate restoration of bone strength
- Combined approach: Optimal pain & local tumour control with ablation
Bone preserving
Image-guided drilling
CT-guided drilling as an alternative to RFA for osteoid osteoma — preserves bone stock with minimal removal.
- Osteoid osteoma: 85–95% success
- Recovery: Protected weight-bearing within 1 week
- Vs open resection: 6–12 week recovery avoided
Indications
Conditions we treat with MIS
A matched view of the lesion, preferred technique and the success rate reported in the literature.
| Condition | Preferred MIS technique | Success rate | Key benefit |
|---|---|---|---|
| Osteoid osteoma | RFA / cryoablation / CT-guided drilling | 94–100% | Complete pain relief, standard of care |
| Primary aneurysmal bone cyst | Percutaneous sclerotherapy (3% polidocanol) | 84–100% | Preserves bone architecture |
| Recurrent ABC | Percutaneous sclerotherapy | 92% | Salvage after failed surgery |
| Simple / unicameral bone cyst | Image-guided drilling / injection | 85–95% | Minimal bone weakening |
| Chondroblastoma (≤2 cm) | RFA / cryoablation | 88–95% | Size-dependent success |
| Extraabdominal desmoid fibromatosis | Percutaneous cryoablation | 85.8% | Non-progressive disease control |
| Bone metastases | Combined ablation + cementoplasty | 90–95% | Pain control + stabilisation |
| Recurrent giant cell tumour | Percutaneous RFA | 100% local control | Joint preservation |
Image guidance
The right modality for every lesion
CT guidance
Intraosseous lesions and procedures requiring bone penetration.
High resolution, thin slices, 3D reconstructions and device compatibility. Mean DLP ~751 mGy·cm² for RFA.
MRI guidance
Soft-tissue tumour margins and real-time temperature monitoring during ablation.
Superior soft-tissue contrast with no ionising radiation.
Ultrasound guidance
Soft-tissue lesions and superficial bone lesions with a soft-tissue component.
86.2–100% diagnostic yield for accessible lesions, true real-time guidance.
Fluoroscopy
Real-time guidance for drilling and hardware placement.
Often combined with CT for complex angulated approaches.
MIS vs open surgery
What the numbers say
1.5 days
Average hospital stay vs 5–7 days for open surgery
2.5–9.1%
Complication rate vs 15–25% for open resection
96%
Performed as day-care with 4-hour observation
~1/3 cost
Of equivalent open procedures
Functional outcomes: patients return to full work duty in around 6 weeks after MIS — compared with 3–6 months for equivalent open surgery — with higher satisfaction scores and superior cosmetic results.
Safety profile
Potential complications, transparently
Major complications occur in only 2.0–2.5% of cases; minor, self-limiting events in 4.8–20.8%.
| Procedure | Major complications | Minor complications | Risk factors |
|---|---|---|---|
| RFA | Fracture (<1%), nerve injury (<1%) | Pain, swelling, skin changes | Long-bone locations |
| Cryoablation | Secondary fracture (1.2%) | Pleural effusion (18.7%), neuropathy | Age >70, >3 cryoprobes |
| Sclerotherapy | Skin necrosis (rare) | Local inflammatory response | Extravasation |
| Biopsy | Bleeding, infection (<1%) | Local haematoma, temporary pain | Coagulopathy |
Looking ahead
The future of MIS in orthopaedic oncology
Navigation & robotics
Real-time navigation and robotic assistance for enhanced precision.
AI-assisted planning
Advanced imaging with AI for procedure planning and outcome prediction.
Multimodal therapy
Combining ablation, cementoplasty and systemic therapy in one pathway.
Expanding indications
Curative-intent MIS for selected primary tumours and spinal applications.
Main take-away
Minimally invasive surgeries in orthopaedic oncology achieve exceptional diagnostic accuracy (93–98%) and therapeutic success (84–100%) through image-guided procedures — offering precise tissue sampling, targeted ablation and bone stabilisation with minimal morbidity and rapid recovery.
Further reading
- Image-guided percutaneous ablation in musculoskeletal oncology — current evidence and outcomes.
- 3% polidocanol sclerotherapy for aneurysmal bone cyst — multicentre series.
- Percutaneous cementoplasty and combined ablation for painful bone metastases.
- Core needle biopsy of bone and soft-tissue tumours — diagnostic accuracy meta-analysis.
Curious if MIS is right for you?
Share your imaging and reports — we'll review whether an image-guided, day-care approach can treat your lesion.
Book an Appointment